INSM

Over the past six months, Insmed's stock (INSM) has trended down by approximately 44.65%. On January 12, 2026, shares gained over 3% after the company reported preliminary sales for full-year 2025 that exceeded forecasts, and outlined expected milestones for 2026. On April 7, 2026, the stock experienced a decline following the announcement that its Phase 2b CEDAR study of brensocatib in hidradenitis suppurativa (HS) missed both primary and secondary endpoints, leading to the discontinuation of the HS program. On May 7, 2026, despite reporting first-quarter 2026 results that exceeded Wall Street's earnings and revenue estimates, Insmed's shares fell by 6.63% in pre-market trading. On May 8, 2026, an analyst from H.C. Wainwright identified the dip as a potential buying opportunity, citing a robust fundamental outlook for BRINSUPRI.